![Robert Lisicki](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Robert Lisicki
Keine laufenden Positionen mehr
Vermögen: - $ am 31.05.2026
Profil
Robert Lisicki worked as Vice President & General Manager at Amgen, Inc. from 2005 to 2014.
From 2014 to 2018, served as Chief Customer Officer, SVP-Sales & Marketing at Daiichi Sankyo, Inc. Between 2018 and 2022, held the position of Chief Commercial Officer & Executive VP at Arena Pharmaceuticals, Inc. Worked at Regeneron Pharmaceuticals, Inc. as General Manager & Vice President-Cardio Metabolic.
From 2022 to 2023, was Chief Executive Officer & Director at InCarda Therapeutics, Inc. Served as Chief Executive Officer & Director at Zura Bio Ltd. from 2024 to 2025.
Held director roles at Adiso Therapeutics, Inc. (2023-2024) and Independent Director at Cadrenal Therapeutics, Inc. (2023-2025).
Education includes undergraduate studies at the State University of New York at Albany.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 20.04.2026 | 0 ( -.--% ) | - $ | 31.05.2026 |
Ehemalige bekannte Positionen von Robert Lisicki
| Unternehmen | Position | Ende |
|---|---|---|
| ZURA BIO LIMITED | Vorstandsvorsitzender | 10.10.2025 |
| CADRENAL THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 15.07.2025 |
Adiso Therapeutics, Inc.
 Adiso Therapeutics, Inc. BiotechnologyHealth Technology Provides biotechnology research services | Direktor/Vorstandsmitglied | 01.08.2024 |
InCarda Therapeutics, Inc.
 InCarda Therapeutics, Inc. BiotechnologyHealth Technology Develops transforming cardiovascular disease treatment through pulmonary delivery of established drugs | Vorstandsvorsitzender | 01.03.2023 |
| ARENA PHARMACEUTICALS | Corporate Officer/Principal | 01.03.2022 |
Ausbildung von Robert Lisicki
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
75
Beziehungen ersten Grades
9
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Regeneron Pharmaceuticals, Inc.
 Regeneron Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops, manufactures and commercializes medicines for diseases | Health Technology |
Arena Pharmaceuticals, Inc.
 Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical products | Health Technology |
State University of New York at Albany
 State University of New York at Albany Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Daiichi Sankyo, Inc.
 Daiichi Sankyo, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceutical products | Health Technology |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology Develops transforming cardiovascular disease treatment through pulmonary delivery of established drugs | Health Technology |
Adiso Therapeutics, Inc.
Adiso Therapeutics, Inc. BiotechnologyHealth Technology Provides biotechnology research services | Health Technology |
Zura Bio Ltd.
 Zura Bio Ltd. BiotechnologyHealth Technology Operates as a multi-asset clinical-stage biotechnology company that focuses on develops novel medicines for immune and inflammatory disorders | Health Technology |
Cadrenal Therapeutics, Inc.
 Cadrenal Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel therapy with orphan drug indication | Health Technology |
